Phaseline

Companies › Suzhou Maximum Bio-tech

Suzhou Maximum Bio-tech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MT027
B7H3-specific CAR-T cells
B7H3Phase 1Advanced Malignant Solid TumorFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06726564MT027Phase 1Advanced Malignant Solid TumorOncologyFeb 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

B7H3 (1)

Companies with the same targets

BioNTech SE Hansoh BioMedical R&D Company Daiichi Sankyo Qilu Pharmaceutical IDEAYA Biosciences MediLink Therapeutics (Suzhou) CSPC Megalith Biopharmaceutical Phrontline Biopharma Aktis Oncology NEOK Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.